Treatment of high-level gentamicin-resistant enterococcus faecalis endocarditis with daptomycin plus ceftaroline

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 4042-4045

  Sakoulas, George ^a   Nonejuie, Poochit ^a   Nizet, Victor ^a   Pogliano, Joseph ^a   Crum Cianflone, Nancy ^b   Haddad, Fadi ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c SHARP GROSSMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTAROLINE; CEFTRIAXONE; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; SULTAMICILLIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; ARTICLE; BACTERIAL MEMBRANE; BLOOD CULTURE; CASE REPORT; CONTINUOUS INFUSION; DIASTOLIC HEART MURMUR; DRUG BINDING; DRUG WITHDRAWAL; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; FEVER; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOST; HUMAN; IN VITRO STUDY; INNATE IMMUNITY; MALE; MINIMUM INHIBITORY CONCENTRATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYSTOLIC HEART MURMUR; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MEMBRANE; CEPHALOSPORINS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECALIS; GENTAMICINS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 84880268579     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02481-12     Document Type: Article

References (10)

1. Rand KH, Houck HJ. 2004. Daptomycin synergy with rifampin and ampicillin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. 53:530-532.
2. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin-and cationic host defense peptide-mediate killing of ampicillin and vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56: 838-844.
3. Rose WE, Schultz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK. 2012. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob. Agents Chemother. 56:5296-5302.
4. Forest Laboratories, Inc. 2012. Ceftaroline fosamil package insert. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/200327s000lbl.pdf. Accessed 10 October 2012.
5. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. 2003. Daptomycin pharmacokineticsandsafety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323.
6. Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev. Infect. Dis. 8(Suppl 5):S503-S511.
7. Patel IH, Chen S, Parsonnet Hackman MR, Brooks MA, Konikoff J, Kaplan SA. 1981. Pharmacokinetics of ceftriaxone in humans. Antimicrob. Agents Chemother. 20:634-641.
8. Pogliano J, Pogliano N, Silverman J. 2012. Daptomycin mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J. Bacteriol. 194:4494-4504.
9. Gavalda J, Len O, Miro JM, Munoz P, Montejo M, Alarcon A, de la Torre-Cisneros J, Pena C, Martinez-Lacasa X, Sarria C, Bou G, Aguado JM, Navas E, Romeu J, Marco F, Torres C, Tornos P, Planes A, Falco V, Almirante B, Pahissa A. 2007. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann. Intern. Med. 146:574-579.
10. Baddour LM, Wilson WR, Bayer AS, Fowler Jr, Bolger VGAF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newbuger JW, Pallasch TJ, Takahashi M, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Councils on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association. Endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434. Pharmacology of Pediatric Antimicrobial Therapy